Charani Ranasinghe Molecular Mucosal Vaccine Immunology Group, Dept Immunology The John Curtin School of Medical Research The Australian National University Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 and excellent B cell immunity
Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 and excellent B cell immunity. Charani Ranasinghe Molecular Mucosal Vaccine Immunology Group, Dept Immunology The John Curtin School of Medical Research The Australian National University. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
The John Curtin School of Medical ResearchThe Australian National University
Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 and excellent B cell immunity
2
Mucosal vaccination induces high quality/avidity HIV-specific CD8 T cells
Induction of high quality/avidity HIV-specific CD8 T cells following mucosal vaccination is associated with lower expression of IL-4/IL-13 by CD8 T cells
Ranasinghe et al. J. Immunol 2007
Ranasinghe et al. Euro J Immunol 2009
Ranasinghe et al. Mucosal Immunology 2013
Absence of IL-4/IL-13 induces high avidity HIV-specific CD8 T cells
Construction of poxviral vector-based vaccines that co-express IL-4R antagonist using homologous recombination
IL-4R antagonist HIV gag/pol/env
Recombinant vaccinia virus (rVV) or Modified Vaccinia Ankara (rMVA) - booster vaccine